Dr. Mark D'Esposito

But that's very different than what's your baseline modularity.

Because you've got to get from your

your you know where your baseline is to this other state and a lot of it has to do is like going from one state to another not not so much sort of the absolute sort of differences so that's that's interesting i didn't know about those results but it's interesting that uh that it does affect sort of connectivity in that way i think the drugs that are going to be helpful are going to are going to promote sort of networks talking to each other as opposed to networks not communicating with each other

Yeah, so I think, you know, I have a lot of patients that I've referred for its approved use, which is depression.

So I'm very excited about sort of the work that's being done for depression.

But we haven't really had any improved anything that's been for, you know, for cognition.

So there are a bunch of studies, anecdotal small studies, where you can give transcranial maxillofacial stimulation, frontal cortex, and working memory improved.

But they really haven't been done in ways that are

We don't know if it generalizes, if it's going to be how, you know, the way it's been done in depression in a way that can really be.

But again, it's just a matter of doing it.

I think it will be part of the things we do, drugs, TMS, and all the other things we've talked about.

It's not just going to be one thing.

And it gets back to networks, right?

What this is doing is really changing how nodes, you know, the interaction of regions.

It's not about sort of just increasing or decreasing activity in some regions.

mysterious part of the brain.

It's this sort of restoring the balance of a network.

Well, I'd say, you know, on behalf of all the neurologists in the world, thank you for appreciating what we do.

It's just so important to try and get this message apart.

Like I said, you know, with patients, we just try to have them understand what it is that they're going through.